Answers are grounded in this paper and cite their sources.
The therapeutic approach to diabetes has deeply changed in recent years due to the increasing availability of new drugs and the publication of a large number of randomized trials and real life studies focused on cardiovascular and renal safety of these drugs. The therapeutic choice following metformin is particularly complex. The most recent guidelines provide the clinician with indications related to efficacy and safety (effects on weight, hypoglycemic risk, effects on cardiovascular risk factors) directing the therapeutic choice above all in the cardiopathic patient. In this brief review is proposed a different attempt to personalize the therapy after metformin, subordinating the choice to the patient’s pathological history. KEY WORDS personalized therapy; efficacy; safety; randomized clinical trials; real word data.
No takes yet. Share an insight, caveat, or question.
Maria Chantal Ponziani (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: